Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2025
상품코드:1704470
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 200 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
성선자극호르몬 방출 호르몬(GnRH) 작용제 시장 규모는 향후 수년간 안정적인 성장세를 보이며 2029년까지 연평균 2.8%의 연평균 복합 성장률(CAGR)로 47억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중 성장의 배경에는 인식 개선 및 조기 진단, 의료비 지출 증가, 불임 치료에서의 사용 증가, 맞춤형 의료에 대한 수요 증가, 연구 자금 및 보조금 증가 등이 있습니다. 예측 기간 중 주요 동향으로는 약물전달 시스템의 발전, 종양학 및 생식 의학의 발전, 호르몬 치료 옵션에 대한 수요 증가, 연구개발 증가, 장시간 작용하는 제제의 부상 등이 있습니다.
호르몬 관련 질환의 유병률 증가는 향후 수년간 성선자극호르몬 방출 호르몬(GnRH) 작용제 시장의 성장을 촉진할 것으로 예상됩니다. 호르몬 관련 질환은 호르몬의 생산과 조절을 담당하는 내분비계의 불균형이나 기능 장애로 인해 발생하는 질환입니다. 여기에는 당뇨병, 갑상선 기능 항진증, 전립선암 등의 질환이 포함됩니다. 호르몬 관련 질환의 유병률 증가는 환경적 영향, 비만, 대사증후군, 유전, 노화 등의 요인에 기인하며, GnRH 작용제는 호르몬 수치 조절에 중요한 역할을 하며, 호르몬 불균형 및 호르몬 의존성 질환과 관련된 병태생리를 치료하기 위한 맞춤화된 접근법을 제공합니다. 개별화된 접근법을 제공합니다. 예를 들어 2023년 12월 호주 통계청은 2022년 인구 약 20명 중 1명, 즉 인구의 5.3%(약 130만 명)가 당뇨병을 앓고 있다고 보고했습니다. 그 유병률은 성별에 따라 남성의 5.8%, 여성의 4.9%가 앓고 있는 것으로 나타났습니다. 또한 당뇨병은 호주에서 7번째 사망원인이며, 그 해 사망자 수는 6,050명이었습니다. 따라서 호르몬 관련 질환의 유병률 증가는 GnRH 작용제 시장의 성장에 박차를 가하고 있습니다.
GnRH 작용제 시장의 기업은 호르몬 민감성 암의 치료 효과와 정확성을 향상시키기 위해 첨단 안드로겐 제거 요법(ADT) 약물 개발에 주력하고 있으며, GnRH 유사체를 포함한 ADT 치료제는 안드로겐 수치를 낮추거나 제거하여 호르몬 민감성 암의 성장을 늦추거나 멈추게 하는 역할을 합니다. 호르몬 민감성 암의 성장을 늦추거나 멈추게 합니다. 예를 들어 2024년 1월 인도 제약회사 자이더스 생명과학(Zaidas Life Sciences)는 렐고릭스(Rergolix)를 렉시고(Lexigo)라는 브랜드로 출시했습니다. 이는 진행성 전립선암의 테스토스테론 억제를 위한 인도 최초이자 유일한 1일 1회 경구용 치료제로, 주사 치료의 필요성을 없앤다. 세계에서 인정받은 유효성분인 레고릭스는 빠른 테스토스테론 억제 효과를 발휘합니다. 렉시고는 인도의 진행성 전립선암에 대한 기존 주사 요법보다 50% 저렴한 가격으로 환자와 의료진에게 안전하고 효과적이며 편리한 치료 옵션을 제공함으로써 전립선암 치료에 큰 진전을 가져다 줄 것입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 고나도트로핀 방출 호르몬(GnRH) 아고니스트 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 성장률 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 실적 : 규모와 성장, 2019-2024
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 고나도트로핀 방출 호르몬(GnRH) 아고니스트 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Leuprorelin
Goserelin
Taltirelin
Histrelin
기타 유형
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 처방별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사제
임플란트
경구
비강 스프레이
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
전립선암
유방암
자궁내막증
자궁근종
이른 발차성 사춘기
불임 치료
기타 용도
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
외래 수술 센터(ASC)
기타 최종사용자
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장, Leuprorelin의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사용 Leuprorelin
이식형 Leuprorelin
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장, Goserelin의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Goserelin 주사제
Goserelin인프란트
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장, Taltirelin의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
주사용 Taltirelin
경구 Taltirelin
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장, Histrelin의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Histrelin 임플란트
Histrelin 주사
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장, 기타 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Triptorelin
Buserelin
Nafarelin
제7장 지역별·국가별 분석
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 경쟁 구도
고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
Ipsen Pharma Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Aurobindo Pharma Limited
Cipla Limited
Dr Reddy's Laboratories Ltd.
Intas Pharmaceuticals Ltd.
Ferring Pharmaceuticals
Amneal Pharmaceuticals Inc.
Endo International plc
Lupin Limited
Gland Pharma Limited
Glenmark Pharmaceuticals Ltd.
Zydus Lifesciences Limited
Bachem Holding AG
Tolmar Pharmaceuticals Inc.
Debiopharm Group
Sun Pharmaceutical Industries Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 2029 : 새로운 기회를 제공하는 국가
고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 2029 : 새로운 기회를 제공하는 부문
고나도트로핀 방출 호르몬(GnRH) 아고니스트 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Gonadotropin-releasing hormone (GnRH) agonists are synthetic drugs that mimic the action of natural GnRH, stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agents are employed to manage hormonal imbalances by regulating hormone levels and are particularly valuable in fertility treatments, where they help control and prevent premature ovulation during procedures such as in vitro fertilization.
The main types of GnRH agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin, a synthetic hormone, is used to treat prostate cancer, endometriosis, and uterine fibroids by decreasing hormone production. It is administered via monthly or quarterly injections and comes in various formulations, such as injectables, implants, oral tablets, and nasal sprays. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Applications of leuprorelin encompass prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, and fertility treatments, with end users including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and other medical facilities.
The gonadotropin-releasing hormone (GnRH) agonists market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists market statistics, including the gonadotropin-releasing hormone (GnRH) agonists industry global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists market share, detailed gonadotropin-releasing hormone (GnRH) agonists market segments, market trends, and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists industry. These gonadotropin-releasing hormone (GnRH) agonists market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $4.1 billion in 2024 to $4.23 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to rising awareness and diagnosis of hormonal disorders, increasing prevalence of hormone-related diseases, increasing prevalence of prostate cancer, growing awareness about hormone therapy, increase demand for long-term safety and efficacy.
The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, rising healthcare expenditure, increasing use in fertility treatments, rising demand for personalized medicine, and increasing research funding and grants. Major trends in the forecast period include advancements in drug delivery systems, advancements in oncology and reproductive medicine, growing demand for hormone therapy options, increasing research and development, and rise of long-acting formulations.
The rising prevalence of hormone-related diseases is expected to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are conditions caused by imbalances or dysfunctions in the endocrine system, which is responsible for producing and regulating hormones. These include diseases such as diabetes, hyperthyroidism, and prostate cancer. The increasing incidence of hormone-related diseases can be attributed to factors like environmental influences, obesity, metabolic syndrome, genetics, and the aging population. GnRH agonists play a crucial role in managing hormone levels and offer a personalized approach to treating conditions linked to hormonal imbalances and hormone-dependent diseases. For example, in December 2023, the Australian Bureau of Statistics reported that in 2022, about one in twenty people, or 5.3% of the population (approximately 1.3 million individuals), were living with diabetes. The prevalence was similar across genders, with 5.8% of males and 4.9% of females affected. Furthermore, diabetes was the seventh leading cause of death in Australia, contributing to 6,050 fatalities that year. Therefore, the increasing prevalence of hormone-related diseases is fueling the growth of the GnRH agonist market.
Companies in the GnRH agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment efficacy and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels, thereby slowing or stopping the growth of hormone-sensitive cancers. For example, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Relugolix under the brand name Rexigo. This is India's first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Relugolix, a globally recognized active ingredient, provides rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable treatments for advanced prostate cancer in India, marking a significant advancement in prostate cancer care by offering a safe, effective, and convenient treatment option for patients and healthcare providers.
In February 2022, Debiopharm, a Switzerland-based manufacturer of GnRH agonists, partnered with Aspen Holdings to launch Trelstar in South Africa. This collaboration aims to introduce Trelstar as a treatment for locally advanced and metastatic hormone-dependent prostate cancer. The partnership is set to deliver a high-quality oncology product, significantly enhancing prostate cancer treatment in the region and improving the overall treatment landscape for affected patients. Aspen Holdings, based in South Africa, provides specialty and generic pharmaceuticals.
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2024. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonadotropin-Releasing Hormone (GnRH) Agonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonadotropin-releasing hormone (gnrh) agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonadotropin-releasing hormone (gnrh) agonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gonadotropin-releasing hormone (gnrh) agonist market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Leuprorelin; Goserelin; Taltirelin; Histrelin; Other Types
2) By Formulation: Injectable; Implants; Oral; Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Prostate Cancer; Breast Cancer; Endometriosis; Uterine Fibroids; Precocious Puberty; Fertility Treatment; Other Applications
5) By End-User: Hospital; Specialty Clinics; Ambulatory Surgical Centers (ASCs); Other End-Users
Subsegments:
1) By Leuprorelin: Injectable Leuprorelin; Implantable Leuprorelin
2) By Goserelin: Goserelin Injection; Goserelin Implant
3) By Taltirelin: Injectable Taltirelin; Oral Taltirelin
4) By Histrelin: Histrelin Implant; Histrelin Injection
5) By Other Type: Triptorelin; Buserelin; Nafarelin
Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Sandoz Group AG; Ipsen Pharma
3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Growth Analysis And Strategic Analysis Framework
5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market Growth Rate Analysis
5.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Total Addressable Market (TAM)
6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Leuprorelin
Goserelin
Taltirelin
Histrelin
Other Types
6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable
Implants
Oral
Nasal Sprays
6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prostate Cancer
Breast Cancer
Endometriosis
Uterine Fibroids
Precocious Puberty
Fertility Treatment
Other Applications
6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Specialty Clinics
Ambulatory Surgical Centers (ASCs)
Other End-Users
6.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Leuprorelin
Implantable Leuprorelin
6.7. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Goserelin Injection
Goserelin Implant
6.8. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Taltirelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Taltirelin
Oral Taltirelin
6.9. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Histrelin Implant
Histrelin Injection
6.10. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triptorelin
Buserelin
Nafarelin
7. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Regional And Country Analysis
7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market
9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market
10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market
11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market
14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market
16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market
18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market
21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market
22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market
24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market
26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market
27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market
28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market
29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market Overview
29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitive Landscape And Company Profiles
